The FDA Pharmacy Compounding Advisory Committee recommended six unapproved peptides for the 503A affirmative compounding list on July 23-24, 2026, and voted against emideltide. FDA scientific reviewers had recommended against all seven. The non-binding vote opens a broader debate about evidence…
On July 23, 24, 2026 , the FDA's Pharmacy Compounding Advisory Committee PCAC voted to recommend six unapproved peptides BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax for the 503A affirmative list of bulk substances that compounding pharmacies may use. The committee voted against a seventh peptide, emideltide . The recommendation is non-binding, and the FDA has not issued a final decision.
The vote came with a notable internal contradiction: FDA scientific reviewers had recommended against all seven peptides, citing insufficient clinical data. The PCAC nevertheless advanced six of them. A second PCAC meeting covering five additional peptides is expected in early 2027 . The list under consideration forms part of a broader push by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. , who has said he wants to broaden access to about 50 unvetted peptides .
The July meeting evaluated a total of seven unapproved peptides. For context, the FDA has approved about 50 peptides as pharmaceutical drugs. Adding these bulk substances to the 503A list would not make them approved drugs; it would permit licensed compounding pharmacies to dispense them to patients with a physician's prescription, under the federal framework established by Section 503A of the FD&C Act .
The PCAC's action breaks down as follows: six peptides advanced with a positive recommendation, and one did not. The list of recommended peptides spans a wide range of purported uses: BPC-157 is often marketed for tendon and gut healing, KPV for inflammation, TB-500 for tissue repair, MOTS-c for metabolic conditions, epitalon for aging-related claims, and semax as a nootropic. Emideltide, the rejected peptide, is less widely known but was evaluated on the same evidentiary standard.
The FDA's scientific reviewers recommended against all seven. Their position rested on the absence of adequate clinical trial evidence for any of these substances in the contexts for which they are marketed. The PCAC's vote does not constitute approval and does not constitute clinical-trial evidence. It is an advisory input to the FDA, which retains final authority.
The timeline explains the immediate context. On July 21, 2026 , MedShadow Foundation published an interview with Joshua Kritzer, Ph.D. , a chemist and peptide researcher at Tufts University , conducted by journalist Sara Talpos . That interview was republished under a Creative Commons license version 4.0 CC BY-NC-ND 4.0 . The republished version frames the discussion with the late-July PCAC evaluation of seven popular unapproved peptides. The interview itself was conducted over Zoom and edited for length and clarity.
The 503A affirmative list is a provision of the FD&C Act that governs the bulk substances compounding pharmacies may use to prepare patient-specific medications. A substance on the list can be used by a licensed compounding pharmacy when a prescriber writes a prescription for an individual patient. It is not a drug approval pathway, and it does not subject the substance to the FDA's premarket safety and efficacy review.
The distinction matters. When a compounding pharmacy uses a bulk substance on the affirmative list, the resulting product is not a new drug in the ordinary regulatory sense, and it cannot be marketed in the way an approved drug can. The legal framework places it closer to a pharmacy-prepared product, with oversight that is structurally different from the clinical trial requirement that governs pharmaceutical drugs.
That clinical trial requirement traces to 1962 , when the federal drug law was amended to require proof of efficacy as well as safety before a drug could be marketed. The 1962 framework is the backbone of modern drug regulation, and it is the standard that FDA scientific reviewers applied when they recommended against all seven peptides. The PCAC vote does not alter that standard, but it does open a legal door for these peptides to reach patients who have a prescription.
The stakes are broader than the seven substances at hand. Secretary Kennedy has argued that peptides are like supplements and may not need to be tested as rigorously as drugs. He has said he wants to broaden access to about 50 unvetted peptides , a number that far exceeds the current slate. The five additional peptides expected at the second PCAC meeting in early 2027 would be a step toward that larger goal.
The gap between these peptides and the FDA-approved peptide drugs is fundamentally a question of evidence. Kritzer, who has studied peptides for more than two decades , described the situation plainly: "I would never recommend anybody to use something that hasn't been proven to be safe." He also said, "When you purchase something that is not an FDA-approved drug, what you're purchasing is a consumer product that has not been tested for efficacy, or even safety."
Kritzer pointed to the history of GLP-1 receptor peptides as a cautionary tale. These peptides first entered human testing for type 2 diabetes about 30 years ago . At the time, researchers understood them primarily as regulators of blood sugar. It took years of human use to reveal that they also act on the brain, the liver, the digestive system, and the cardiovascular system. The pleiotropic effects that made drugs like Ozempic and Mounjaro blockbusters were not predicted at the outset.
The lesson, Kritzer argued, is that peptide biology is not reducible to a simple circuit diagram. "Biology is way more complicated than we know; it's not like a computer, or iPhone, or something, where we understand exactly how each circuit works," he said. For a peptide with no human clinical data, he added, "We probably have no idea what that peptide is doing in your body."
The problem of anecdotal evidence compounds the issue. Kritzer noted that a patient might cite 10 papers to support an anecdote about a peptide, but that a handful of mechanistic or animal studies does not establish human safety or efficacy. Anecdotes are subject to confirmation bias, and they do not prove causation.
The Peptide Atlas trial registry data offers a concrete picture of how thin the clinical evidence is for two of the recommended peptides. TB-500 , also known as thymosin beta 4, has 10 registered clinical trials on file. The phase breakdown is Phase 2: 5, Phase 3: 3, Phase 1: 2 . The status breakdown is completed: 6, recruiting: 3, terminated: 1 .
Some of those trials are substantive. NCT07586865 is a Phase 2 recruiting study of recombinant human thymosin beta 4 for acute myocardial infarction. NCT07487363 is a Phase 2 recruiting trial of TB-500, described as the thymosin beta 4 17-23 fragment, for cardiovascular biomarkers in stable atherosclerotic cardiovascular disease. NCT05555589 is a Phase 3 recruiting trial of RGN-259 ophthalmic solution for neurotrophic keratopathy. NCT05984134 and NCT05485818 are completed Phase 2 trials in acute myocardial infarction. NCT03937882 is a completed Phase 3 trial of RGN-259 for dry eye syndrome.
So TB-500 has a genuine, if uneven, clinical development history in specific niches. The 44 indexed PubMed papers on file include recent work on thymosin beta-4-derived peptides for Alzheimer's disease, cardiac remodeling, and fat graft survival. Third-party lab purity tests on file number 5 , with a highest observed purity of 99.98% . Purity, however, is not efficacy.
MOTS-c has a much thinner clinical record. Peptide Atlas has 4 registered clinical trials on file: Phase 2: 1 , with a status breakdown of recruiting: 3, active: 1 . The notable trials include NCT07678073, a recruiting study of MOTS-c levels in renal transplantation; NCT07505745, a Phase 2 recruiting trial of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity; NCT03878706, a recruiting cardiovascular study involving GLP-1 agonists and SGLT2 inhibitors; and NCT06133946, an active study of deafness-gene screening.
The 112 indexed PubMed papers on MOTS-c cover a broad swath of preclinical work, including recent papers on metabolic signaling in mesenchymal stromal cells, cardiac inflammasome suppression in diabetic rats, inflammatory lung disease, cardiac ischemia reperfusion injury, and soft tissue transplantation survival. But the only interventional clinical trial testing MOTS-c as a therapeutic agent appears to be the Phase 2 insulin sensitivity study, which is still recruiting. The gap between the preclinical enthusiasm and the human evidence is wide, and it is exactly the gap the FDA's scientific reviewers pointed to.
For clinicians, the PCAC vote creates a pragmatic dilemma. A non-binding advisory recommendation in favor of six peptides, combined with FDA reviewers' opposition, leaves the evidentiary question unresolved. A clinician who prescribes BPC-157 or MOTS-c under the 503A framework, if the FDA ultimately adopts the recommendation, would be prescribing a substance that has not met the 1962 efficacy standard. The legal exposure shifts accordingly.
Kritzer's distinction is essential here. Supplements are regulated like consumer products, similar to ground beef or strollers. Recourse for harm is largely limited to lawsuits against manufacturers. Gray-market peptides present an even harder case: they may lack an identifiable company to sue if they cause harm. A patient who buys a peptide injection from an unregulated source has no clear legal path to recovery, and no safety monitoring to catch adverse effects early.
For researchers, the development is a double-edged sword. On one hand, a pathway for compounding access could accelerate real-world observation of these peptides and generate signals worth testing formally. On the other hand, the absence of controlled data means that any clinical signal will be confounded by variability in sourcing, dosing, and purity, the very variables that make observational data unreliable.
The supply chain question is separate but urgent. Compounding pharmacies that wish to use these substances need a reliable source of bulk material that meets pharmacopeial standards. The Peptide Atlas purity data on TB-500 and MOTS-c, with high observed purities of 99.98% and 99.894% respectively, suggest that high-quality material can be sourced. But purity of the input material does not address the safety of the peptide in the human body, and it does not address the consistency of the finished compounded product.
The PCAC vote does not change the fundamental fact that the evidentiary gap described in the July 21 interview has not been closed. The FDA has not made a final decision. The agency could follow the PCAC recommendation, follow its scientific reviewers, or split the difference. Each outcome is possible, and each would send a different message about the evidentiary standard for peptide products.
Several specific questions remain open. Will the FDA issue a final decision on the seven peptides, and will it follow the PCAC recommendation or its own reviewers' advice? What are the five additional peptides to be considered at the second PCAC meeting in early 2027? Will any of the recommended peptides undergo formal clinical trials to close the evidentiary gap, or will the 503A pathway become a substitute for drug development? What human safety and efficacy data, if any, exist for BPC-157, KPV, TB-500, MOTS-c, epitalon, semax, and emideltide?
There is also a deeper scientific question about how the field should evaluate peptides that show promise in animal models but have not been tested in humans. Kritzer noted that over the Past…
Peptides referenced: BPC-157, TB-500, Semaglutide, Tirzepatide, MOTS-c, Epithalon, Semax, Thymosin Beta-4.
Related reading: Cyclized Cecropin A Peptide Reaches Phase IIa for CRAB Pneumonia, GLP-1 multi-target therapies and manufacturing near 2025 milestones, First Woman Wins Emil Fischer Medal for Synthetic Peptide Research, Copenhagen's New Protein Design Center Opens With 109 Million Dollar Grant.